[Asia Economy Reporter Kang Nahum] Samsung Biologics announced on the 29th that it has signed a letter of intent for a contract worth 49 billion KRW with MSD for the contract manufacturing of biopharmaceuticals.



The contract amount corresponds to 4.21% of the company's sales revenue in the most recent fiscal year.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing